GI
PVLA

GAMMA Investing’s Palvella Therapeutics PVLA Stock Holding History

GAMMA Investing’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.65K Buy
37
+9
+32% +$1.09K ﹤0.01% 3417
2026
Q1 		$3.49K Buy
28
+7
+33% +$730 ﹤0.01% 3499
2025
Q4 		$2.2K Buy
21
+4
+24% +$341 ﹤0.01% 3572
2025
Q3 		$1.07K Buy
+17
New +$758 ﹤0.01% 3600

Other funds holding PVLA

SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

GAMMA Investing's PVLA Position: Q2 2026 in Review

GAMMA Investing increased its Palvella Therapeutics (PVLA) stake by 32% in Q2 2026, buying an estimated $1.09K and bringing the position to 37 shares worth $5.65K. The position accounts for ﹤0.01% of the portfolio, ranked #3417.

GAMMA Investing first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. 5 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • GAMMA Investing held 37 shares of Palvella Therapeutics worth $5.65K as of Q2 2026.
  • GAMMA Investing bought 9 Palvella Therapeutics shares in Q2 2026, an estimated $1.09K.
  • Palvella Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3417 holding.
  • GAMMA Investing first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 5 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.